Having taken place at Champalimaud Foundation, in Lisbon, Portugal, from the 14th to the 16st of November, the consortium reviewed the progress and discussed new future opportunities.


During our third General Assembly meeting, the members of the different work packages presented an update of their research projects within the consortium, successfully meeting a series of objectives that lead us to the final year of the project.

We are extremely excited with the discussion we had at the General Assembly meeting and grateful for the Scientific Advisory Board advice.

We look forward to the year ahead working together with our partners to find therapeutical possibilities for metastatic uveal melanoma.